Privia Health (PRVA) Q4 2025 Earnings Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRVA
Wall Street analysts forecast PRVA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.430
Low
23.00
Averages
30.40
High
34.00
Current: 23.430
Low
23.00
Averages
30.40
High
34.00
About PRVA
Privia Health Group, Inc. is a technology-driven, national physician-enablement company. The Company collaborates with medical groups, health plans and health systems. It enhances physician practices, improves patient experiences and doctors for delivering care in both in-person and virtual care settings. Its Privia Platform is powered by the Privia Technology Solution, an end-to-end, cloud-based technology solution that integrates both Privia-developed and third-party applications into an interface and workflow that manages all aspects of its Privia Providers provision of healthcare services. Privia Platform optimizes provider workflow across the full continuum of reimbursement arrangements. The Company provides management services to each Medical Group though a local management services organization, which provides Medical Groups with access to value-based care (VBC) opportunities either directly or through Privia-owned accountable care organizations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Privia Health CEO Sells 121,086 Shares for $2.73 Million
- Executive Sell-off: Privia Health CEO Parth Mehrotra sold 121,086 shares between May 11 and 12, 2026, for approximately $2.73 million, reducing his direct stake by 21.80% to 434,357 shares, which may indicate a weakening confidence in the company's future prospects.
- Transaction Context: This sale marks the largest single open-market transaction by Mehrotra on record, suggesting an acceleration in sale size likely due to a declining number of shares available for sale, indicating that future large sales may not be sustainable.
- Market Reaction and Analysis: Despite the company reporting over 25% year-over-year revenue growth in Q1 and expanding into New Jersey, Mehrotra's sell-off could raise investor concerns about the company's outlook, especially given mixed analyst opinions on earnings risks tied to inflation.
- Investor Considerations: The stock sale was executed under a Rule 10b5-1 trading plan, with some shares sold to cover tax withholding obligations, reminding investors that insider transactions may not necessarily reflect confidence in the stock and should be interpreted with caution.
See More
Privia Health CEO Sells 121,086 Shares for $2.73 Million
- Executive Share Sale: Privia Health CEO Parth Mehrotra sold 121,086 shares between May 11 and 12, 2026, for approximately $2.73 million at an average price of $22.56 per share, representing a significant 21.80% reduction in his direct holdings, indicating a notable decrease in his ownership stake.
- Transparent Trading Plan: The share sale was conducted under a Rule 10b5-1 trading plan, meaning the transactions were executed on a predetermined schedule, with some shares sold to cover tax withholding obligations, reflecting compliance and transparency in executive trading activities.
- Strong Financial Performance: Privia Health reported over 25% year-over-year revenue growth in its Q1 2026 results, driven by same-store growth and new provider additions, demonstrating the company's success in expanding its market presence and enhancing operational efficiency.
- Mixed Market Reactions: While J.P. Morgan raised its price target from $33 to $45 and maintained an overweight rating, Barclays cut its target from $45 to $24, indicating concerns about the company's future profitability, which has contributed to an approximately 8% decline in stock price year-to-date.
See More
Rubicon Founders Increases Stake in Privia Health Group
- Increased Holdings: Rubicon Founders LLC increased its stake in Privia Health Group by 175,142 shares in Q1 2026, with an estimated transaction value of $3.95 million, indicating a bullish outlook as the stock now represents 88.92% of its 13F reportable AUM.
- Financial Performance: Privia Health reported a 22% year-over-year revenue growth in 2025, reaching $2.1 billion, with net income rising 59% to $22.9 million, showcasing its strong market position and demand for its services in the healthcare sector.
- Market Expectations: In Q1 2026, Privia Health's revenue grew 26% year-over-year to $603.8 million, with full-year revenue projected to reach around $2.4 billion, indicating that its solutions are addressing unmet needs in the healthcare industry and boding well for future success.
- Investment Value: The increase in holdings by Rubicon Founders positions Privia Health's stock as a core asset in its portfolio, reflecting a positive long-term investment outlook that may attract further investor interest.
See More
Rubicon Founders Increases Stake in Privia Health Group
- Increased Holdings: Rubicon Founders purchased an additional 175,142 shares of Privia Health Group in Q1 2026, with an estimated trade value of $3.95 million, indicating a strong bullish sentiment as this stock now constitutes 88.92% of the fund's reportable AUM.
- Strong Financial Performance: Privia Health Group reported $2.1 billion in revenue for 2025, marking a 22% year-over-year increase, while net income surged 59% to $22.9 million, reflecting robust market demand and profitability in the healthcare sector.
- Healthy Balance Sheet: As of 2025, Privia Health's total assets stood at $1.4 billion against total liabilities of $578.4 million, with no debt, showcasing a solid financial position that supports future growth initiatives.
- Optimistic Future Outlook: In Q1 2026, Privia Health's revenue rose 26% year-over-year, with full-year projections estimating around $2.4 billion, indicating that its solutions are effectively addressing unmet needs in the healthcare industry, thus presenting significant long-term investment potential.
See More
Privia Health Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Privia Health reported a Q1 non-GAAP EPS of $0.19, missing expectations by $0.06, while revenue reached $603 million, reflecting a 25.6% year-over-year increase and exceeding estimates by $41.07 million, indicating strong market performance.
- Guidance Update for 2026: The company maintained its full-year 2026 outlook for most metrics, raising the guidance range for Attributed Lives to between 1.6 million and 1.625 million, showcasing confidence in future growth prospects.
- Operational Efficiency Improvement: It is expected that approximately 80% of Adjusted EBITDA will convert to free cash flow in 2026, enhancing the company's financial flexibility and supporting future investments.
- Market Expansion Plans: Privia Health targets a 19.5% growth in Adjusted EBITDA for 2026 while expanding its footprint to 24 states, further solidifying its competitive position in the national market.
See More
Privia Health (PRVA.US) Director Plans to Sell $40.47 Million in Common Stock via Form 144
Share Sale Announcement: Matthew Shawn Morris intends to sell 1.63 million shares of Privia Health (PRVA.US) on May 1, with a total market value of approximately $40.47 million.
Reduction in Shareholding: Since February 26, 2026, Morris has reduced his shareholding in Privia Health by 24,338 shares, valued at approximately $608.36K.
See More
Privia Health CEO Sells 121,086 Shares for $2.73 Million
- Executive Sell-off: Privia Health CEO Parth Mehrotra sold 121,086 shares between May 11 and 12, 2026, for approximately $2.73 million, reducing his direct stake by 21.80% to 434,357 shares, which may indicate a weakening confidence in the company's future prospects.
- Transaction Context: This sale marks the largest single open-market transaction by Mehrotra on record, suggesting an acceleration in sale size likely due to a declining number of shares available for sale, indicating that future large sales may not be sustainable.
- Market Reaction and Analysis: Despite the company reporting over 25% year-over-year revenue growth in Q1 and expanding into New Jersey, Mehrotra's sell-off could raise investor concerns about the company's outlook, especially given mixed analyst opinions on earnings risks tied to inflation.
- Investor Considerations: The stock sale was executed under a Rule 10b5-1 trading plan, with some shares sold to cover tax withholding obligations, reminding investors that insider transactions may not necessarily reflect confidence in the stock and should be interpreted with caution.
See More
Privia Health CEO Sells 121,086 Shares for $2.73 Million
- Executive Share Sale: Privia Health CEO Parth Mehrotra sold 121,086 shares between May 11 and 12, 2026, for approximately $2.73 million at an average price of $22.56 per share, representing a significant 21.80% reduction in his direct holdings, indicating a notable decrease in his ownership stake.
- Transparent Trading Plan: The share sale was conducted under a Rule 10b5-1 trading plan, meaning the transactions were executed on a predetermined schedule, with some shares sold to cover tax withholding obligations, reflecting compliance and transparency in executive trading activities.
- Strong Financial Performance: Privia Health reported over 25% year-over-year revenue growth in its Q1 2026 results, driven by same-store growth and new provider additions, demonstrating the company's success in expanding its market presence and enhancing operational efficiency.
- Mixed Market Reactions: While J.P. Morgan raised its price target from $33 to $45 and maintained an overweight rating, Barclays cut its target from $45 to $24, indicating concerns about the company's future profitability, which has contributed to an approximately 8% decline in stock price year-to-date.
See More
Rubicon Founders Increases Stake in Privia Health Group
- Increased Holdings: Rubicon Founders LLC increased its stake in Privia Health Group by 175,142 shares in Q1 2026, with an estimated transaction value of $3.95 million, indicating a bullish outlook as the stock now represents 88.92% of its 13F reportable AUM.
- Financial Performance: Privia Health reported a 22% year-over-year revenue growth in 2025, reaching $2.1 billion, with net income rising 59% to $22.9 million, showcasing its strong market position and demand for its services in the healthcare sector.
- Market Expectations: In Q1 2026, Privia Health's revenue grew 26% year-over-year to $603.8 million, with full-year revenue projected to reach around $2.4 billion, indicating that its solutions are addressing unmet needs in the healthcare industry and boding well for future success.
- Investment Value: The increase in holdings by Rubicon Founders positions Privia Health's stock as a core asset in its portfolio, reflecting a positive long-term investment outlook that may attract further investor interest.
See More
Rubicon Founders Increases Stake in Privia Health Group
- Increased Holdings: Rubicon Founders purchased an additional 175,142 shares of Privia Health Group in Q1 2026, with an estimated trade value of $3.95 million, indicating a strong bullish sentiment as this stock now constitutes 88.92% of the fund's reportable AUM.
- Strong Financial Performance: Privia Health Group reported $2.1 billion in revenue for 2025, marking a 22% year-over-year increase, while net income surged 59% to $22.9 million, reflecting robust market demand and profitability in the healthcare sector.
- Healthy Balance Sheet: As of 2025, Privia Health's total assets stood at $1.4 billion against total liabilities of $578.4 million, with no debt, showcasing a solid financial position that supports future growth initiatives.
- Optimistic Future Outlook: In Q1 2026, Privia Health's revenue rose 26% year-over-year, with full-year projections estimating around $2.4 billion, indicating that its solutions are effectively addressing unmet needs in the healthcare industry, thus presenting significant long-term investment potential.
See More
Privia Health Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Privia Health reported a Q1 non-GAAP EPS of $0.19, missing expectations by $0.06, while revenue reached $603 million, reflecting a 25.6% year-over-year increase and exceeding estimates by $41.07 million, indicating strong market performance.
- Guidance Update for 2026: The company maintained its full-year 2026 outlook for most metrics, raising the guidance range for Attributed Lives to between 1.6 million and 1.625 million, showcasing confidence in future growth prospects.
- Operational Efficiency Improvement: It is expected that approximately 80% of Adjusted EBITDA will convert to free cash flow in 2026, enhancing the company's financial flexibility and supporting future investments.
- Market Expansion Plans: Privia Health targets a 19.5% growth in Adjusted EBITDA for 2026 while expanding its footprint to 24 states, further solidifying its competitive position in the national market.
See More
Privia Health (PRVA.US) Director Plans to Sell $40.47 Million in Common Stock via Form 144
Share Sale Announcement: Matthew Shawn Morris intends to sell 1.63 million shares of Privia Health (PRVA.US) on May 1, with a total market value of approximately $40.47 million.
Reduction in Shareholding: Since February 26, 2026, Morris has reduced his shareholding in Privia Health by 24,338 shares, valued at approximately $608.36K.
See More
